DB18948InvestigationalProtein Based Therapies
Petosemtamab is under investigation in clinical trial NCT03526835 (A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors).
- Mechanism
- Curator reviewed
Pharmacologically active on Epidermal growth factor receptor and Leucine-rich repeat-containing G protein-coupled receptor 5
- Code names
- MCLA-158
Resolves to
Compound
Targets
What you can answer from here — as of July 09, 2026
Which drugs share a target with Petosemtamab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account